The hepatitis diagnostic and treatment market was valued at US$XX billion in 2017 and is projected to expand at a CAGR of XX.XX% over the forecast period to reach US$XX billion by 2023. Hepatitis means inflammation of the liver. There are several hepatitis viruses that have been categorized as Hepatitis A, B, C, D, E, and G and among them hepatitis A, B, and C are most common. According to World Health Organization’s global hepatitis report 2017, hepatitis B and C are responsible for 96% of all hepatitis mortality. Rising number of hepatitis infected population, growing consumption of alcohol and drugs and improved accessibility to hepatitis drug are the major factors that are driving the market’s growth. With new developments taking place in the treatment of hepatitis virus, and global players expanding their footprint across geographies to provide medication for the disease are the factors that will boost the hepatitis diagnostic and treatment market growth.
By type, the hepatitis diagnostic and treatment market has been broadly segmented into diagnostic and treatment. The hepatitis virus is diagnosed through various methods such as blood test, DNA test, Liver biopsy, RNA testing and liver ultrasound and is treated with drugs, injectable alpha interferons and in adverse cases liver transplant. Hepatitis B and C are considered as chronic viral hepatitis that are treated via antiviral medicines and injected alpha interferons.
By Disease Type
By disease type, the hepatitis diagnostic and treatment market has been segmented into Hepatitis A, B, C, and others. Others include Hepatitis D, E, and G. Hepatitis B and C are the most spread diseases around the world. Hepatitis B is endemic in China and eastern Asia where most people become infected during childhood.
Geographically, the hepatitis diagnostic and treatment market has been segmented into North America, Europe, Middle East & Africa, Asia-Pacific and South America region. North America accounts for the major share in the market owing to the advanced health infrastructure, accessibility of new drugs and growing awareness among people about the disease.
The hepatitis diagnostic and treatment market is competitive owing to the presence of major players and regional vendors in the market. The global key players are Novartis AG, F. Hoffmann-La Roche Ltd, Merk & Co., Inc., Vertex Pharmaceuticals Incorporated, Bristol-Myers Squibb Company, GlaxoSmithKline plc, Gilead, Bayer AG, AbbVie Inc., and Janssen Pharmaceuticals, Inc.
The hepatitis diagnostic and treatment market has been analyzed through following segments:
Injectable alpha Interferons
By Disease Type
Middle East and Africa
Key insights offered in “Hepatitis Diagnostic and Treatment Market Report: Trends, Forecast and Competitive Analysis”
What will be the hepatitis diagnostic and treatment market size from 2018 to 2023?
How are the major drivers and restraints affecting the hepatitis diagnostic and treatment market growth and the opportunities which exist for key vendors?
What are the business risks and threats involved in the hepatitis diagnostic and treatment market?
Which segment of the market and region will drive or lead the market growth and why?
A comprehensive analysis of competitive landscape and key market participants’ behavior
Key strategies being adopted by vendors, with in-depth analysis along with their impact on competition and market growth.
Analysis on growth opportunities in different applications and regions of hepatitis diagnostic and treatments.
Analysis of competitive intensity of the industry based on Porter’s Five force model
All our studies come with 2 months of analyst support.
We are in compliance with the global privacy laws.